[1]曾 涛,何 浓,熊福生.阿仑膦酸钠维D3片对骨质疏松合并股骨颈骨折患者髋关节置换术后假体周围骨密度及骨代谢指标的影响[J].医学信息,2024,37(11):98-101.[doi:10.3969/j.issn.1006-1959.2024.11.018]
　ZENG Tao,HE Nong,XIONG Fu-sheng.Effect of Alendronate Sodium and Vitamin D3 Tablets on Periprosthetic Bone Mineral Density and Bone Metabolism Indexes in Patients with Osteoporosis Complicated with Femoral Neck Fracture After Hip Replacement[J].Journal of Medical Information,2024,37(11):98-101.[doi:10.3969/j.issn.1006-1959.2024.11.018]
点击复制

阿仑膦酸钠维D3片对骨质疏松合并股骨颈骨折患者髋关节置换术后假体周围骨密度及骨代谢指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年11期
页码:
98-101
栏目:
论著
出版日期:
2024-06-01

文章信息/Info

Title:
Effect of Alendronate Sodium and Vitamin D3 Tablets on Periprosthetic Bone Mineral Density and Bone Metabolism Indexes in Patients with Osteoporosis Complicated with Femoral Neck Fracture After Hip Replacement
文章编号:
1006-1959（2024）11-0098-04
作者:
曾 涛; 何 浓; 熊福生
（1.川北医学院中西医结合系，四川 南充 637000；2.川北医学院附属遂宁市中医院骨二科，四川 遂宁 629099）
Author(s):
ZENG Tao; HE Nong; XIONG Fu-sheng
(1.Department of Integrative Medicine,North Sichuan Medical College,Nanchong 637000,Sichuan,China;2.The Second Department of Orthopdics,Suining Hospital of Traditional Chinese Medicine Affiliattedto North Sichuan Medical College,Suining 629099,Sichuan,China)
关键词:
阿仑膦酸钠维D3片; 骨质疏松症; 股骨颈骨折; 髋关节置换术; 骨代谢标志物; 骨密度
Keywords:
Alendronate sodium and vitamin D3 tablets; Osteoporosis; Femoral neck fracture; Hip replacement; Bone metabolism markers; Bone mineral density
分类号:
R683
DOI:
10.3969/j.issn.1006-1959.2024.11.018
文献标志码:
A
摘要:
目的 探讨阿仑膦酸钠维D3片对骨质疏松合并股骨颈骨折患者髋关节置换术后假体周围骨密度及骨代谢指标的影响。方法 选取2021年3月-2022年11月川北医学院附属遂宁市中医院收治的50例骨质疏松症合并股骨颈骨折患者作为研究对象，利用随机数字表法分为试验组及对照组，各25例。对照组术后给予碳酸钙D3片治疗，试验组在其基础上给予阿仑膦酸钠维D3片治疗，比较两组患侧股骨粗隆骨密度、血清骨钙素、Ⅰ型前胶原N-端前肽及骨特异性碱性磷酸酶水平及不良反应发生率。结果 试验组治疗后6个月股骨粗隆骨密度高于对照组（P＜0.05）；试验组治疗后6个月血清骨钙素、Ⅰ型前胶原N-端前肽及血清骨特异性碱性磷酸酶水平低于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 阿仑膦酸钠维D3片能够调节骨代谢，有效预防因骨质疏松性股骨颈骨折而行髋关节置换术患者术后假体周围骨量丢失，且应用安全性高。
Abstract:
Objective To investigate the effects of alendronate sodium and vitamin D3 tablets on periprosthetic bone mineral density and bone metabolism indexes in patients with osteoporosis and femoral neck fracture after hip replacement.Methods A total of 50 patients with osteoporosis complicated with femoral neck fracture admitted to Suining Hospital of Traditional Chinese Medicine Affiliated to North Sichuan Medical College from March 2021 to November 2022 were selected as the research objects. They were divided into experimental group and control group by random number table method, with 25 patients in each group. The control group was treated with calcium carbonate D3 tablets after operation, and the experimental group was treated with alendronate sodium vitamin D3 tablets on the basis of the control group. The femoral trochanter bone mineral density, serum osteocalcin, procollagen type I N-terminal propeptide， bone-specific alkaline phosphatase levels and incidence of adverse reactions were compared between the two groups.Results The bone mineral density of femoral trochanter in the experimental group was higher than that in the control group at 6 months after treatment (P<0.05). The levels of serum osteocalcin, type I procollagen N-terminal propeptide and serum bone-specific alkaline phosphatase in the experimental group were lower than those in the control group at 6 months after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Alendronate sodium and vitamin D3 tablets can regulate bone metabolism, effectively prevent periprosthetic bone loss in patients undergoing hip replacement due to prevention of osteoporotic femoral neck fracture, and have high application safety.

参考文献/References:

[1]Shanb AA,Youssef EF.The impact of adding weight-bearing exercise versus nonweight bearing programs to the medical treatment of elderly patients with osteoporosis[J].J Family Community Med,2014,21(3):176-181.[2]Yi Z,Bin S,Jing Y,et al.Tranexamic Acid Administration in Primary Total Hip Arthroplasty:A Randomized Controlled Trial of Intravenous Combined with Topical Versus Single-Dose Intravenous Administration[J].J Bone Joint Surg Am,2016,98(12):983-991.[3]Rahman WA,Amenábar T,Hetaimish BM,et al.Outcome of Revision Total Hip Arthroplasty in Management of Failed Metal-on-Metal Hip Arthroplasty[J].J Arthroplasty,2016,31(11):2559-2563.[4]王康振,杨健松,张会良,等.骨力胶囊联合阿仑膦酸钠维D3片治疗老年骨质疏松的疗效及对骨代谢标记物及骨强度的影响[J].中国老年学杂志,2018,38(4):864-866.[5]中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.[6]Schulman RC,Weiss AJ,Mechanick JI.Nutrition,bone,and aging: an integrative physiology approach[J].Curr Osteoporos Rep,2011,9(4):184-195.[7]Feng J,Liu S,Ma S,et al.Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-κB signaling pathway[J].Acta Biochim Biophys Sin (Shanghai),2014,46(12):1024-1033.[8]Venesmaa PK,Kr?觟ger HP,Miettinen HJ,et al.Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry--a 3-year follow-up study[J].J Bone Miner Res,2001,16(6):1056-1061.[9]康鹏德,裴福兴,王坤正.假体周围骨溶解发生的细胞、分子生物学机制及早期诊断和药物治疗[J].中华骨科杂志,2008,28(8):684-687.[10]沈一飞,纪翠芳,李欢,等.阿法骨化醇联合阿伦磷酸钠维D3片治疗老年骨质疏松的临床疗效及其对骨代谢标志物的影响[J].中国老年学杂志,2022,42(11):2710-2712.[11]Okimoto N,Uemura Y,Yoshioka T,et al.Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open-label,prospective,observational study[J].Health Sci Rep,2018,2(1):e107.[12]Shen J,Ke Z,Dong S,et al.Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis[J].Med Sci Monit,2022,28:e935491.[13]von Knoch F,Eckhardt C,Alabre CI,et al.Anabolic effects of bisphosphonates on peri-implant bone stock[J].Biomaterials,2007,28(24):3549-3559. [14]Morita A,Kobayashi N,Choe H,et al.Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty,2-year follow-up: a randomized controlled trial[J].J Orthop Surg Res,2020,15(1):17.[15]Zhou J,Liu B,Qin MZ,et al.Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study[J].Orthop Surg,2020,12(3):890-899.[16]Khanizadeh F,Rahmani A,Asadollahi K,et al.Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis[J].Arch Endocrinol Metab,2018,62(4):438-445.[17]Kavanagh KL,Guo K,Dunford JE,et al.The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs[J].Proc Natl Acad Sci U S A,2006,103(20):7829-7834.[18]Parveen B,Parveen A,Vohora D.Biomarkers of Osteoporosis: An Update[J].Endocr Metab Immune Disord Drug Targets,2019,19(7):895-912.[19]张炳坤,张喜善.骨代谢标志物在骨质疏松症诊治中的应用[J].中国矫形外科杂志,2022,30(16):1483-1486.[20]Shane E,Burr D,Abrahamsen B,et al.Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research[J].J Bone Miner Res,2014,29(1):1-23.

相似文献/References:

[1]汪钦生,邵 敏,姜 涛.绝经后妇女中骨质疏松患者血清钙磷、骨代谢指标与BMD的关系[J].医学信息,2019,32(04):1.[doi:10.3969/j.issn.1006-1959.2019.04.001]
　WANG Qin-sheng,SHAO Min,JIANG Tao.Relationship between Serum Calcium,Phosphorus and Bone Metabolism Markers and BMD in Postmenopausal Women with Osteoporosis[J].Journal of Medical Information,2019,32(11):1.[doi:10.3969/j.issn.1006-1959.2019.04.001]
[2]李 红,孔令泉,吴凯南.乳腺癌相关骨质疏松症的发病机制及防治[J].医学信息,2020,33(07):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
　LI Hong,KONG Ling-quan,WU Kai-nan.Pathogenesis and Prevention of Breast Cancer Associated Osteoporosis[J].Journal of Medical Information,2020,33(11):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
[3]刘 纳,李玉兰,许明芳,等.2型糖尿病临床期肾病与骨密度及骨代谢标记物的相关性研究[J].医学信息,2020,33(08):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
　LIU Na,LI Yu-lan,XU Ming-fang,et al.Study on the Relationship Between Bone Mineral Density and Bone Metabolism Markers in Stage IV Nephropathy of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2020,33(11):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
[4]石耀武,陶宝琛,张宏蕾.西安地区骨质疏松症的影响因素及中医证型分布[J].医学信息,2020,33(11):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
　SHI Yao-wu,TAO Bao-chen,ZHANG Hong-lei.Influencing Factors of Osteoporosis in Xi’an and Distribution of TCM Syndromes[J].Journal of Medical Information,2020,33(11):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
[5]米尔阿地力·麦麦提依明,阿卜杜萨拉木·亚克甫,沈志敏.骨质疏松对全膝关节置换术后康复的影响[J].医学信息,2021,34(09):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
　Mieradili·Maimaitiyiming,Abudusalamu·Yakepu,SHEN Zhi-min.Effect of Osteoporosis on Rehabilitation After Total Knee Arthroplasty[J].Journal of Medical Information,2021,34(11):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
[6]李泽芹.降钙素联合阿仑膦酸盐治疗原发性骨质疏松症有效性评价[J].医学信息,2021,34(17):154.[doi:10.3969/j.issn.1006-1959.2021.17.041]
　LI Ze-qin.Evaluation of the Effectiveness of Calcitonin Combined with Alendronate Sodium in the Treatment of Primary Osteoporosis[J].Journal of Medical Information,2021,34(11):154.[doi:10.3969/j.issn.1006-1959.2021.17.041]
[7]朱道信,罗志环,陈少健,等.唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响[J].医学信息,2021,34(23):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
　ZHU Dao-xin,LUO Zhi-huan,CHEN Shao-jian,et al.Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis[J].Journal of Medical Information,2021,34(11):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
[8]冯欢欢.骨质疏松症中医理论研究的文献计量学分析[J].医学信息,2022,35(16):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
　FENG Huan-huan.Bibliometric Analysis of TCM Theoretical Research on Osteoporosis[J].Journal of Medical Information,2022,35(11):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
[9]张 宁,夏晓黎,王亚锋,等.慢性阻塞性肺疾病合并骨质疏松症危险因素的Meta分析[J].医学信息,2022,35(24):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
　ZHANG Ning,XIA Xiao-li,WANG Ya-feng,et al.Meta-analysis of Risk Factors for Chronic Obstructive Pulmonary Disease Complicated with Osteoporosis[J].Journal of Medical Information,2022,35(11):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
[10]周奕良,毛国庆.基于网络药理学和分子对接技术探讨淫羊藿苷治疗骨质疏松症的作用机制[J].医学信息,2023,36(05):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]
　ZHOU Yi-liang,MAO Guo-qing.The Mechanism of Icariin in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking Technology[J].Journal of Medical Information,2023,36(11):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]

更新日期/Last Update: 1900-01-01